John Oyler (Photographer: Paul Yeung/Bloomberg via Getty Images)

Fast-grow­ing BeiGene blue­prints 42-acre R&D and man­u­fac­tur­ing cam­pus in the US, with plans to hire 'hun­dred­s'

BeiGene has made its pres­ence in the US known with the FDA ap­proval of its on­col­o­gy treat­ment two years ago, and its five of­fices across the coun­try. Tues­day, the com­pa­ny an­nounced that it will add a sixth lo­ca­tion, this time an R&D and man­u­fac­tur­ing cam­pus, in Hopewell, NJ, near­ly 60 miles away from its oth­er of­fice in the re­gion.

The new cam­pus will be built on a 42-acre site. The fa­cil­i­ty will in­clude com­mer­cial-stage man­u­fac­tur­ing, clin­i­cal R&D and the “BeiGene Cen­ter for Phar­ma­covig­i­lance In­no­va­tion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.